Seres Therapeutics Inc【MCRB】株式ニュース | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc (MCRB) ニュース

Seres Therapeutics Inc (MCRB)

0.98

0.065

(7.10%)

終了 12月2日 6:00AM

0.9533

-0.0267

(-2.72%)

取引時間後: 6:50AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 1...

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call...

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome...

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 25...

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 13...

Form DEF 14A - Other definitive proxy statements

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption...

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call...

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief...

Form 8-K - Current report

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive...

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

3
4
5
次へ

BurgerKing82

BurgerKing82 1日前

Appears to be a good biotech

FrostyStar1

FrostyStar1 2週前

The are looking for a partner which would share in burn. You seem to be clueless.

FrostyStar1

FrostyStar1 2週前

He ran away cause he was wrong. He was a pumper.

TrendTrade2016

TrendTrade2016 2週前

MCRB..HERE WE GO

TrendTrade2016

TrendTrade2016 2週前

MCRB DOLLA RUNNER

Carmen for the win

Carmen for the win 2月前

Dear Mon Ami JeanFM, I hope all is well. Do you have any news from Switzerland?

Cosa

Acquisition offer? Old news..we heard it first from JeanFM lol.

glenn1919

glenn1919 3月前

MCRB......................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

Cosa

Holding nothing. This management is Terrible. They will need to raise funds within 8 months further diluting shareholders. They burn nearly $40 million a quarter. The money they're getting from the sale will not last long. SER-155 will be a specialty drug which equals little revenue if it even makes it that far. This is just my opinion and I have been wrong many times. Good luck if you are holding.

Cosa

Reduced position to 15% of original holding. Average profit of 40%, taking the win. Management makes this company risky!

Cosa

Exited another 10% of position. Taking some off the table just in case...

Cosa

Bought the dip at $1.10 the other day and sold that today and %5 more of my core position. Will start another position if it dips again.

glenn1919

glenn1919 4月前

MCRB...........................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 4月前

TechandBio

TechandBio 4月前

Feel Great about the $2.00 calls I bought yesterday.
Close over 1.50 next!

$MCRB

TechandBio

TechandBio 4月前

was buying Seres for .77 a month ago. I'm holding for $2.00+ same for $ICCM expect a similar move soon.

$MCRB

Cosa

The past few days have been great! Sold off 15% of my position today. Taking some off the table for profits.

glenn1919

glenn1919 5月前

MCRB.....................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783

TechandBio

TechandBio 5月前

Just sold my MCRB for a double. Looking for a 10x in ICCM Cure early breast cancer 97% after multiple 5 year independent data studies and late stage breast cancer data with large tumors 93%
$MCRB

RiddleGuru99

RiddleGuru99 5月前

Jeanfm. Any update on this or is it basically dead?

ConnorMic

ConnorMic 5月前

are u still there Jean fm

ConnorMic

ConnorMic 6月前

He has loads of rsu’s at 3 bucks and 5 bucks. He would come out swimming if they sold the whole company. To me he is flagships guy though so he’ll do whatever they tell him and seems like flagship wants to keep things moving as a clinical stage company. See-155 is phase 1. No way nestle partners and gives them upfront cash at this point. They might sell the rest of the portfolio to someone else or partner with someone. As it stands today this would go from a pharma with revenue and a commercialized product to a very early stage bio and it’s hard to imagine long term institutional investors are over the moon about this. So if it stays as is can’t believe they have the vote and stock price is giving them that signal. Lots of time for them to change the deal.

Cosa

Selling the company is out for one simply reason. Management doesn't hold too much shares. For instance CEO Eric Shaff's salary in 2023 was estimated to be about $685k with other compensation totaling over $3m. According to my etrade account Eric holds 140,698 shares on 5/15/2024. If Nestle offered $5.20 a share, that make his shares worth $731,629. I'm not sure how many more options or RSU's would vest which would increase this number. But $700k is an easy "No" for him as he would be out of a job and makes more keeping it. This is all my opinion and for entertainment purposes.

https://finance.yahoo.com/news/increases-seres-therapeutics-inc-nasdaq-164726562.html

Cosa

If they do sell VOWST and strike a deal for SER-155, that would be more bullish.

This is from SER-109 article in 2021 but changed it to SER-155 for entertainment purposes.
Under the terms of the agreement, Nestlé Health Science will utilize its global pharmaceutical business Aimmune Therapeutics and will assume the role of lead commercialization party. Seres will receive license payments of $175 million up front, and an additional $125 million upon FDA approval of SER-155. The agreement also includes sales target milestones which, if achieved, could total up to $225 million. Seres will be responsible for development and pre-commercialization costs in the U.S. Upon commercialization, Seres will be entitled to an amount equal to 50% of the commercial profits.

Original Article:
https://www.businesswire.com/news/home/20210701005405/en/Seres-Therapeutics-Nestl%C3%A9-Health-Science-Announce-SER-109-Co-Commercialization-License-Agreement

Cosa

Not sure if shareholders would vote in favor of $230M. Maybe up to $300M

If you read this from the article below. And based on their last ER. They have about $102M in liabilities. They have cash of about $125M, which is expected to be runway to Q4 2024.

With capital expected from transaction they will pay off $102M and have a cash runway to Q4 2025. They are going to sell the remaining 50% rights for about $230M. This would pay off debt and leave them with $250M cash runway. Assuming that $125M was our runway to Q4 this year and another $125M is for the year 2025. Probably have a milestone payment in there also.

Clip from article below.
Seres expects to use the capital from this transaction to fully retire its senior secured debt facility with Oaktree Capital Management, and support the further advancement of SER-155 and its other cultivated microbiome product candidates. Based on Seres' current cash, its future operating plans, and the capital expected to be obtained from the transaction, the Company anticipates being able to extend its cash runway into Q4 2025, subject to performance under the transition services agreement.
Source:
https://ih.advfn.com/stock-market/NASDAQ/seres-therapeutics-MCRB/stock-news/93996839/seres-therapeutics-enters-into-memorandum-of-under

All just made up numbers for entertainment purposes.

ConnorMic

ConnorMic 6月前

Comment v’as Tu Jean. As Tu encore des connection chez nestle? As tu des nouvelles?

ConnorMic

ConnorMic 6月前

At the time maybe that was total shares outstanding ? Maybe minus the ones nestle already owns.

ConnorMic

ConnorMic 6月前

Agreed merci Jean

Cosa

Tomorrow $0.75 needs to hold

Carmen for the win

Carmen for the win 6月前

Dear Jean, thank you for the info you have shared. In one of your previous posts you wrote "119000000 À 5.20" what did you mean by that?

Cosa

I'm no longer doubting that you knew something. Just didn't work in the way it was originally planned. Thanks Jean

ConnorMic

ConnorMic 6月前

Ok merci Jean. Pense-Tu que seres a du non valeur apres ca ?

JeanFM

J'AI VU LE PROJET CHEZ VEVE L'OFFRE ÉTAIT 5,20 $ POUR CHAQUE ACTION DE SERES CLASSE A

Nestlé S.A voulait que l'entreprise et les actionnaires soient payés. Blâmez la direction et non Nestlé S.A ici à Veve

JeanFM

L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024

JeanFM

L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024

JeanFM

L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024

Cosa

If that is the case, Seres shareholders would be absolutely angered. EGM and fire everyone. But we won't know unless Nestle goes public with the offer. Which I doubt they will, because if they ink this deal in would be a win win for them. They would have full rights to VOWST and not have to take on Seres debt.

JeanFM

l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune

JeanFM

l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune

JeanFM

l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune

JeanFM

l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune

andrewflying

andrewflying 6月前

Thank you for your input! Could you please elaborate on what you said regarding the news for next week. Apparently, the market hates today's announcement.

Cosa

This is bad news. Seres will be going backwards to a clinical stage company. The only long term benefit will be whatever Royalty deal they can secure for VOWST. With the deal they currently have in place Nestle already has 50% of the rights. They have already paid $175M upfront and another $125M after the approval. So currently Nestle is in for $300M. On the PR today the terms say any new deal will basically terminate the previous deal. So the remaining $225M milestone payments are out. How much is the remaining 50% rights worth? Maybe they will try $500M with new milestone payments + a small percentage or sales?

But in the end if you look at where Seres is today, they have about $125M cash runway (This is with the $300M they got the past 2 years). So even if they get a $500M, it will only take about 2 years for that money to be gone. The cost of RD is really expensive. SER-155 is still in phase 1!

Seres entered into an agreement with Nestlé Health Science in July 2021 to jointly commercialize SER-109 in the U.S. and Canada. Under the terms of the agreement, Nestlé Health Science will use its global pharmaceutical business, Aimmune Therapeutics, and will assume the role of lead commercialization party. Seres has received an upfront license payment of $175 million and will receive an additional $125 million upon FDA approval of SER-109. The agreement also includes sales target milestones which, if achieved, would total up to $225 million. Seres will be responsible for development and pre-commercialization costs in the U.S. Upon commercialization, Seres will be entitled to an amount equal to 50% of the commercial profits.

Source: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-announces-confirmatory-results

ConnorMic

ConnorMic 6月前

Tu nous a dit le prix de seres est 5.20

FrostyStar1

FrostyStar1 6月前

You said Nestle was getting the company for 5.20 that didn't happen

Nestle gets vowst and shareholders get nothing

Carmen for the win

Carmen for the win 6月前

Dear Jean, could you please explain what you mean by the 119000000 number?
thank you

QueenVolcano96

QueenVolcano96 6月前

Why MCRB share price is not $5.20 yet? Seems no acquisition at $5.20 a share?

JeanFM

Oui VOWST, Nestle S.A ou VOWST

Le prix convenu sur cette offre est de 5 dollars et 20 cents

J'ai vu l'accord de Nestlé S.A.

J'ai raison. J'ai dit du 5 au 9 juin pour un accord.

119000000 À 5.20

JeanFM

Oui VOWST, Nestle S.A ou VOWST

Le prix convenu sur cette offre est de 5 dollars et 20 cents

J'ai vu l'accord de Nestlé S.A.

J'ai raison. J'ai dit du 5 au 9 juin pour un accord.

119000000 À 5.20

FrostyStar1

FrostyStar1 6月前

Not true, you said Nestle gets the company. Nestle does not get the company.

Seres Therapeutics

Vontobel Financial Produ...

IT0005603482 20250321 40...

Xtrackers MSCI Europe ES...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約